Episode: 75 - Are Licensing Fees Required or Gatekeeping?
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
Episode: 75 - Are Licensing Fees Required or Gatekeeping?
-
Gesprochen von:
-
Von:
Über diesen Titel
July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wilkinson, CEO of Gamma Proteins, discuss accessing antibody discovery technology through licensing fees and royalties—and whether these fees are justified or not. Wilkinson delves into the current landscape of antibody discovery technologies, including if AI-based technology warrants fees, how royalties affect both small companies and big pharma, and his background as one of the first experts in the field who offered purely free-for-service options. He also shares what excites him about antibody engineering and beyond.
Links from this episode:
Mythic Therapeutics
Gamma Proteins
